TNFRSF17 and plasma cell myeloma: Given that BCMA downregulation has also been reported as a mechanism of resistance in clinical trials11,12, we aimed to validate MT-SLP-76 in a model of multiple myeloma with low BCMA expression (OPM-2 cells, 1,200 molecules per cell; Fig. 4a).